- Home
- NWBI vs AGIO Comparison
NWBI vs AGIO Comparison
Compare NWBI & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWBI
- AGIO
- Stock Information
- Founded
- NWBI 1896
- AGIO 2007
- Country
- NWBI United States
- AGIO United States
- Employees
- NWBI N/A
- AGIO N/A
- Industry
- NWBI Major Banks
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- NWBI Finance
- AGIO Health Care
- Exchange
- NWBI Nasdaq
- AGIO Nasdaq
- Market Cap
- NWBI 1.6B
- AGIO 1.4B
- IPO Year
- NWBI N/A
- AGIO 2013
- Fundamental
- Price
- NWBI $13.29
- AGIO $34.85
- Analyst Decision
- NWBI Hold
- AGIO Buy
- Analyst Count
- NWBI 1
- AGIO 6
- Target Price
- NWBI $15.00
- AGIO $58.60
- AVG Volume (30 Days)
- NWBI 629.8K
- AGIO 567.3K
- Earning Date
- NWBI 07-22-2025
- AGIO 07-31-2025
- Dividend Yield
- NWBI 6.21%
- AGIO N/A
- EPS Growth
- NWBI N/A
- AGIO N/A
- EPS
- NWBI 0.90
- AGIO 11.45
- Revenue
- NWBI $518,578,999.00
- AGIO $37,035,000.00
- Revenue This Year
- NWBI $7.29
- AGIO $22.30
- Revenue Next Year
- NWBI $11.29
- AGIO $219.19
- P/E Ratio
- NWBI $14.32
- AGIO $2.91
- Revenue Growth
- NWBI N/A
- AGIO 25.96
- 52 Week Low
- NWBI $10.75
- AGIO $23.42
- 52 Week High
- NWBI $15.42
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- NWBI 61.38
- AGIO 52.40
- Support Level
- NWBI $12.47
- AGIO $32.53
- Resistance Level
- NWBI $12.93
- AGIO $34.34
- Average True Range (ATR)
- NWBI 0.24
- AGIO 1.28
- MACD
- NWBI 0.05
- AGIO -0.31
- Stochastic Oscillator
- NWBI 80.00
- AGIO 20.98
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.